Latest Advances in Lung Cancer Research

Tarlatamab combined with a PD-L1 inhibitor as maintenance therapy achieved a 25-month median survival in advanced small cell lung cancer — results experts called unprecedented.

Lung Cancer Foundation of America (LCFA) developed the Saving Lungs Behind The Chair℠ campaign to address these health inequities by leveraging trusted relationships in the Black community via licensed beauty hair professionals in Metro Atlanta.

Tarlatamab extends survival and reduces side effects for small cell lung cancer patients, emerging as a promising new second-line treatment option.

Researchers used multi-omics (genetic, protein-related) data to find new molecular weaknesses in non-small cell lung cancer and offering fresh avenues for therapies.

A five-biomarker blood test combining cfDNA levels and gene methylation patterns detected lung cancer with 84% accuracy, offering a promising non-invasive early screening tool.

A 65-year-old surfer overcame early-stage EGFR-positive lung cancer using stereotactic body radiation therapy (SBRT), a precise, non-surgical treatment that spared his lung capacity.

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.

A new study provides the first genetic evidence that air pollution causes DNA mutations leading to lung cancer in people who have never smoked, helping explain why lung cancer rates are rising among never-smokers worldwide, particularly women and those of Asian ancestry.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Lung cancer cases in never-smokers are increasing, driven by air pollution and genetic mutations, particularly affecting women and younger patients.

Dana-Farber’s EQUAL study tests blood screening for EGFR mutations in Asian and Hispanic never-smokers at high lung cancer risk.